Metastatic castration-resistant prostate cancer (CRPC): preclinical and clinical evidence for the sequential use of novel therapeutics (Q38181005)

30 August 2017

title

Metastatic castration-resistant prostate cancer (CRPC): preclinical and clinical evidence for the sequential use of novel therapeutics (English)

1 reference

30 August 2017

1 reference

5

Johann de Bono

1 reference

30 August 2017

Deborah Mukherji

1

1 reference

30 August 2017

Aurelius Omlin

series ordinal

2

1 reference

30 August 2017

Carmel Pezaro

series ordinal

3

1 reference

30 August 2017

Ali Shamseddine

series ordinal

4

1 reference

30 August 2017

publication date

1 September 2014

1 reference

Cancer and Metastasis Reviews

30 August 2017

published in

1 reference

30 August 2017

volume

33

1 reference

30 August 2017

issue

2-3

1 reference

30 August 2017

page(s)

555-566

1 reference

Cancer mortality in Europe, 2000-2004, and an overview of trends since 1975.

30 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9473-1

Sipuleucel-T immunotherapy for castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9473-1

Abiraterone and increased survival in metastatic prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9473-1

Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9473-1

Enzalutamide--a major advance in the treatment of metastatic prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9473-1

Alpha emitter radium-223 and survival in metastatic prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9473-1

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9473-1

Abiraterone in metastatic prostate cancer without previous chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9473-1

Improved survival in a cohort of trial participants with metastatic castration-resistant prostate cancer demonstrates the need for updated prognostic nomograms

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9473-1

Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9473-1

Can whole-body magnetic resonance imaging with diffusion-weighted imaging replace Tc 99m bone scanning and computed tomography for single-step detection of metastases in patients with high-risk prostate cancer?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9473-1

Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9473-1

Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9473-1

Treatment of hormone-refractory prostate cancer with docetaxel or mitoxantrone: relationships between prostate-specific antigen, pain, and quality of life response and survival in the TAX-327 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9473-1

Interdisciplinary critique of sipuleucel-T as immunotherapy in castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9473-1

A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9473-1

Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9473-1

Increased survival with enzalutamide in prostate cancer after chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9473-1

Management of metastatic castration-resistant prostate cancer: recent advances

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9473-1

Abiraterone and novel antiandrogens: overcoming castration resistance in prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9473-1

Steroid hormone receptors in prostate cancer: a hard habit to break?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9473-1

The mutational landscape of lethal castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9473-1

Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9473-1

Interactions of abiraterone, eplerenone, and prednisolone with wild-type and mutant androgen receptor: a rationale for increasing abiraterone exposure or combining with MDV3100.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9473-1

Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9473-1

Testosterone and dihydrotestosterone tissue levels in recurrent prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9473-1

Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9473-1

Intratumoral de novo steroid synthesis activates androgen receptor in castration-resistant prostate cancer and is upregulated by treatment with CYP17A1 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9473-1

Abiraterone inhibits 3β-hydroxysteroid dehydrogenase: a rationale for increasing drug exposure in castration-resistant prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9473-1

Effects of abiraterone acetate on androgen signaling in castrate-resistant prostate cancer in bone

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9473-1

Resistance to CYP17A1 inhibition with abiraterone in castration-resistant prostate cancer: induction of steroidogenesis and androgen receptor splice variants

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9473-1

Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9473-1

Development of a second-generation antiandrogen for treatment of advanced prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9473-1

Androgen receptor splice variants mediate enzalutamide resistance in castration-resistant prostate cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9473-1

Taxane-induced blockade to nuclear accumulation of the androgen receptor predicts clinical responses in metastatic prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9473-1

Drug resistance in metastatic castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9473-1

Cabazitaxel in metastatic castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9473-1

Preclinical antitumor activity of cabazitaxel, a semisynthetic taxane active in taxane-resistant tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9473-1

Phase 3, randomized, controlled trial of atrasentan in patients with nonmetastatic, hormone-refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9473-1

GRADE: an emerging consensus on rating quality of evidence and strength of recommendations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9473-1

Antitumour activity of docetaxel following treatment with the CYP17A1 inhibitor abiraterone: clinical evidence for cross-resistance?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9473-1

Phase I and pharmacokinetic study of XRP6258 (RPR 116258A), a novel taxane, administered as a 1-hour infusion every 3 weeks in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9473-1

Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9473-1

Clinical activity of abiraterone acetate in patients with metastatic castration-resistant prostate cancer progressing after enzalutamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9473-1

Enzalutamide in castration-resistant prostate cancer patients progressing after docetaxel and abiraterone

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9473-1

Tubulin-Targeting Chemotherapy Impairs Androgen Receptor Activity in Prostate Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9473-1

Docetaxel-based combination therapy for castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9473-1

Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9473-1

Antitumour activity of enzalutamide (MDV3100) in patients with metastatic castration-resistant prostate cancer (CRPC) pre-treated with docetaxel and abiraterone

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-013-9473-1

10.1007/S10555-013-9473-1

21 January 2018

Identifiers

DOI

1 reference

Dimensions Publication ID

30 August 2017

1003695905

0 references

1 reference